anal squamous cell carcinoma (Cancer)
Information
- Disease name
- anal squamous cell carcinoma
- Disease ID
- DOID:5525
- Description
- "An anal carcinoma that arises near the squamocolumnar junction." [url:http\://en.wikipedia.org/wiki/Anal_cancer]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02560298 | Active, not recruiting | Phase 2 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer | August 23, 2016 | August 2023 |
| NCT02437851 | Active, not recruiting | Phase 2 | Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection | April 2015 | March 21, 2026 |
| NCT01115790 | Completed | Phase 1 | A Phase 1 Study in Participants With Advanced Cancer | February 2010 | January 2016 |
| NCT04616196 | Completed | Phase 1/Phase 2 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | October 30, 2020 | March 30, 2023 |
| NCT01807546 | Completed | Phase 2 | Oral Rigosertib for Squamous Cell Carcinoma | March 2013 | April 2016 |
| NCT01285778 | Completed | Phase 2 | Vectibix for the Treatment of Anal Cancer | October 2010 | March 24, 2017 |
| NCT05130073 | Completed | 4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer | July 31, 2019 | December 14, 2023 | |
| NCT05060471 | Enrolling by invitation | Phase 2 | PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients | September 8, 2021 | June 30, 2024 |
| NCT06050707 | Recruiting | Phase 2 | MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach | September 29, 2023 | September 1, 2028 |
| NCT04929028 | Recruiting | Phase 2 | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | August 9, 2022 | September 15, 2029 |
| NCT05374252 | Recruiting | Phase 3 | Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients | May 7, 2022 | December 31, 2025 |
| NCT05438836 | Recruiting | Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer | January 1, 2022 | January 1, 2031 | |
| NCT05838391 | Recruiting | N/A | Adaptive Radiation in Anal Cancer | May 18, 2023 | December 31, 2028 |
| NCT05328765 | Recruiting | A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection | June 9, 2023 | October 2024 | |
| NCT04596033 | Terminated | Phase 1 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | November 11, 2020 | June 27, 2022 |
| NCT02407561 | Terminated | Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays | February 2015 | July 2016 | |
| NCT05582031 | Withdrawn | Phase 2 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers | April 30, 2023 | April 30, 2025 |
- Disase is a (Disease Ontology)
- DOID:4908
- Cross Reference ID (Disease Ontology)
- NCI:C9161
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:255084004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1412036
- Exact Synonym (Disease Ontology)
- Epidermoid anal carcinoma